The import of insulin in dosage forms to the US is expected to grow steadily from 2024 to 2028, reaching 4.6394 million kilograms by 2028. In 2023, the volume was approximately 4.39 million kilograms. The year-on-year growth rate varies slightly, indicating modest increases annually. The compound annual growth rate (CAGR) for the forecast period is consistent, showcasing a stable rise in imports.
Future trends to watch for include:
- Potential impacts of new diabetes management technologies that could alter demand for traditional insulin forms.
- Regulatory changes affecting insulin pricing and import policies.
- Emerging markets and new suppliers entering the US market, potentially affecting import dynamics.
- Advancements in insulin delivery systems that may influence overall consumption patterns.
